


CLAIMS

What is claimed is:

1. A composition comprising one or more compounds represented by the structure of Formula (I):



and/or at least one salt thereof, wherein:

R₁ is -CH₂CF₃ or -CH₂CH₂CF₃;

R₂ is -CH₂CF₃, -CH₂CH₂CF₃, or -CH₂CH₂CH₂CF₃;

R₃ is H, -CH₃ or R_x;

R₄ is H or R_y;

R_x

is: -CH₂OC(O)CH(CH₃)NH₂, -CH₂OC(O)CH(NH₂)CH(CH₃)₂, -CH₂OC(O)CH((C

H(CH₃)₂)NHC(O)CH(NH₂)CH(CH₃)₂, -CH₂OC(O)CH₂-, or

-CH₂OC(O)CH₂C(CH₃)₂-, or -CH₂OC(O)--CH₂OP(O)(OH)₂;

R_y is: -SCH₂CH(NH₂)C(O)OH, -SCH₂CH(NH₂)C(O)OH₃,

or -SCH₂CH(NH₂)C(O)OC(CH₃)₃;

Ring A is phenyl or pyridinyl;

each R_a is independently F, Cl, -CN, -OCH₃, C₁₋₃ alkyl, -CH₂OH, -CF₃,

cyclopropyl, -OCH₃, -O(cyclopropyl) and/or -NHCH₂CH₂OCH₃;


each R_b is independently F, Cl, -CH₃, -CH₂OH, -CF₃, cyclopropyl, and/or -OCH₃;

y is zero, 1 or 2; and

z is zero, 1, or 2,


in combination with an additional cancer therapeutic agent.

2. The composition of claim 1, wherein the compound of Formula (I) is represented by the structure of Compound (1):




(1)

3. The composition of claim 1, wherein the compound of Formula (I) is represented by the structure of Compound (2):




(2)

4. The composition of claim 1, wherein the compound of Formula (I) is represented by the structure of Compound (22):



(22).

5. The composition of any one of claims 1-4, wherein said additional cancer therapeutic agent comprises one or more inhibitors of mammalian target of rapamycin (mTOR) and cisplatin.
6. The composition of claim 5, wherein said mTOR inhibitor comprises Everolimus.
7. A method of treating, suppressing or inhibiting a proliferative disease in a subject comprising the step of administering to said subject a first composition comprising a first composition comprising one or more compounds represented by the structure of Formula (I):



and/or at least one salt thereof, wherein:

R₁ is -CH₂CF₃ or -CH₂CH₂CF₃;

R₂ is -CH₂CF₃, -CH₂CH₂CF₃, or -CH₂CH₂CH₂CF₃;

5 R₃ is H, -CH₃ or R_x;

R₄ is H or R_y;

R_x

is: -CH₂OC(O)CH(CH₃)NH₂, -CH₂OC(O)CH(NH₂)CH(CH₃)₂, -CH₂OC(O)CH((C

H(CH₃)₂)NHC(O)CH(NH₂)CH(CH₃)₂, -CH₂OC(O)CH₂-,

-CH₂OC(O)CH₂C(CH₃)₂-, or -CH₂OC(O)-;

R_y is: -SCH₂CH(NH₂)C(O)OH, -SCH₂CH(NH₂)C(O)OH₃,

or -SCH₂CH(NH₂)C(O)OC(CH₃)₃;

Ring A is phenyl or pyridinyl;

each R_a is independently F, Cl, -CN, -OCH₃, C₁₋₃ alkyl, -CH₂OH, -CF₃,

15 cyclopropyl, -OCH₃, -O(cyclopropyl) and/or -NHCH₂CH₂OCH₃;

each R_b is independently F, Cl, -CH₃, -CH₂OH, -CF₃, cyclopropyl, and/or -OCH₃;

y is zero, 1 or 2; and

z is zero, 1, or 2

and a second composition comprising an additional cancer therapeutic agent.

20 8. The method of claim 7, wherein said proliferative disease is a pre-cancerous condition or a benign proliferative disorder.


9. The method of claim 8, wherein said proliferative disease is a cancer.

10. The method of claim 9, wherein said cancer comprises Adenoid Cystic Carcinoma (ACC).

11. The method of claim 9, wherein said cancer comprises a lymphoma.


25 12. The method of claim 9, wherein said cancer comprises breast cancer.

13. The method of claim 12, wherein said breast cancer comprises triple negative breast cancer
14. The method of claim 9, wherein said cancer comprises endometrial cancer.
15. The method of claim 9, wherein said cancer comprises non-small cell lung cancer (NSCLC).
16. The method of claim 9, wherein said cancer comprises multiple myeloma.
- 5 17. The method of claim 9, wherein said cancer comprises leukemia.
18. The method of claim 17, wherein said leukemia comprises T-cell acute lymphoblastic leukemia (T-ALL) or T-lymphoblastic leukemia/lymphoma (TLL).
19. The method of claim 9, wherein said cancer comprises a Desmoid tumor.
20. The method of any one of claims 7-19, wherein said first composition and/or said second
- 10 composition is intravenously administered to said subject.
21. The method of any one of claims 7-19, wherein said first composition and/or said second composition is orally administered to said subject.
22. The method of any one of claims 7-21, wherein said first composition and said second composition are administered together.
- 15 23. The method of any one of claims 7-21, wherein said first composition and said second composition are administered at separate sites or at separate times.
24. The method of claim 23, wherein said first composition comprising Formula (I) is administered prior to and then again subsequent to the administration of said second composition comprising said mTOR inhibitor.
- 20 25. The method of any one of claims 7-24, wherein the compound of Formula (I) comprises:




(1)

26. The method of any one of claims 7-24, wherein the compound of Formula (I) comprises:



(2)

27. The method of any one of claims 7-24, wherein the compound of Formula (I) comprises:



28. The method of any one of claims 7-27, wherein said additional cancer therapeutic agent
5 comprises one or more inhibitors of mammalian target of rapamycin (mTOR) and cisplatin.
29. The method of claim 28, wherein said mTOR inhibitor comprises Everolimus.
30. The method of claim 9, wherein said cancer comprises a Notch-activating mutation.